Nicoletta Loggia
Chief Tech/Sci/R&D Officer at ORCHARD THERAPEUTICS PLC
Net worth: - $ as of 30/04/2024
Nicoletta Loggia active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 09/09/2021 | - |
| CANDEL THERAPEUTICS, INC. | Director/Board Member | 07/06/2023 | - |
| Independent Dir/Board Member | 07/06/2023 | - |
Career history of Nicoletta Loggia
Training of Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Statistics
International
| United Kingdom | 2 |
| Italy | 2 |
| United States | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Nicoletta Loggia
- Experience
